Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 15 IN PLASTIC CONTAINER.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day, administered at a rate of 200 mL/hour, adjusted based on metabolic and fluid needs.
None Documented
None Documented
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution